Skip to main content
. 2010 May 24;28(20):3219–3226. doi: 10.1200/JCO.2009.27.1825

Fig 2.

Fig 2.

(A) Disease-free survival (DFS) in patients with stage II disease and defective DNA mismatch repair (dMMR) by treatment status. (B) DFS in patients with stage III disease and dMMR by treatment status. (C) DFS in patients with stage II disease and proficient MMR (pMMR) by treatment status. (D) DFS in patients with stage III disease and pMMR by treatment status. HR, hazard ratio; FU, fluorouracil.